The biopharmaceutical industry has been highly criticized for a number of years with respect to the high costs of medicines, particularly for drugs to treat cancer and rare diseases. Physicians and insurers have challenged the benefit of a new drug that might cost tens of thousands of dollars yet only extends life for a few months. This has led to various ethical debates about the value of life vs. the cost to society as a whole.
Image: http://www.freedigitalphotos.net
To read the original article: What Price Innovation? The Sovaldi Saga
